FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anna Kettermann

Research Profile

Chemicals & Drugs

Prostate Specific Antigen

Disorders

Prostatic Neoplasms

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.
Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Shari Miura Ling; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging.
Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anna Kettermann (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.
Urology 2011;77(1):143-7.
2010: Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Shari Miura Ling; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging.
BJU international 2010;106(1):28-31.
2010: Ashley E Ross; Stacy Loeb; Patricia Landis; Alan W Partin; Jonathan I Epstein; Anna Kettermann; Zhaoyong Feng; H Ballentine Carter; Patrick C Walsh
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(17):2810-6.
2010: Phillip M Pierorazio; Luigi Ferrucci; Anna Kettermann; Dan L Longo; E Jeffrey Metter; H Ballentine Carter
Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging.
BJU international 2010;105(6):824-9.
2010: Jeffrey J Tosoian; Stacy Loeb; Anna Kettermann; Patricia Landis; Debra J Elliot; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Lori J Sokoll
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.
The Journal of urology 2010;183(2):534-8.
2009: Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Luigi Ferrucci; Anna Kettermann; E Jeffrey Metter
Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging.
The Journal of urology 2009;182(6):2646-51.
2009: Stacy Loeb; Anna Kettermann; H Ballentine Carter; Luigi Ferrucci; E Jeffrey Metter; Patrick C Walsh
Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging.
The Journal of urology 2009;182(4):1458-62.
2009: Stacy Loeb; H Ballentine Carter; Patrick C Walsh; William B Isaacs; Anna Kettermann; Toshiko Tanaka; Luigi Ferrucci; E Jeffrey Metter
Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level.
The Journal of urology 2009;182(1):101-4; discussion 105.
2009: Edward M Schaeffer; H Ballentine Carter; Anna Kettermann; Stacy Loeb; Luigi Ferrucci; Patricia Landis; Bruce J Trock; E Jeffrey Metter
Prostate specific antigen testing among the elderly--when to stop?
The Journal of urology 2009;181(4):1606-14; discussion 1613-4.
2008: Stacy Loeb; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter; H Ballentine Carter
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.
European urology 2008;54(5):1073-80.
2008: Stacy Loeb; Anna Kettermann; H Ballentine Carter; Luigi Ferrucci; E Jeffrey Metter; Patrick C Walsh
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.
The Journal of urology 2008;180(4):1314-7; discussion 1317.
2007: H Ballentine Carter; Anna Kettermann; Christopher A Warlick; E Jeffrey Metter; Patricia Landis; Patrick C Walsh; Jonathan I Epstein
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
The Journal of urology 2007;178(6):2359-64; discussion 2364-5.
2007: H Ballentine Carter; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
Urology 2007;70(4):685-90.
2006: H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; EDWARD WRIGHT; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Journal of the National Cancer Institute 2006;98(21):1521-7.